Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Polyphor AG
  6. News
  7. Summary
    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by EnBiotix

09/10/2021 | 01:31am EDT

EQS Group-Ad-hoc: Polyphor AG / Key word(s): Agreement Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by EnBiotix 10-Sep-2021 / 07:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Allschwil, Switzerland, September 10, 2021

Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by EnBiotix Polyphor (SIX: POLN) and EnBiotix Inc., a privately held late clinical-stage rare disease company currently focused on products for rare, chronic respiratory diseases, today announced closing of the previously announced purchase agreement of inhaled murepavadin. As a result of closing the transaction, Polyphor received the agreed payment of 2'599'655 of common shares of EnBiotix (15.4% fully diluted of EnBiotix) at an agreed valuation of USD 10 million.

Following the closing of the inhaled murepavadin purchase agreement, the companies will take the next steps with respect to the merger agreement, which was signed simultaneously. The planned merger is subject to a number of closing conditions, including approval by Polyphor and EnBiotix shareholders, and is expected to be closed in Q4 2021.

For further information please contact:

For Investors:          For Media: 
Hernan Levett           Dr. Stephan Feldhaus 
Chief Financial Officer Feldhaus & Partner 
Polyphor Ltd.           +41 79 865 92 56 
+41 61 567 16 00        feldhaus@feldhaus-partner.ch 
IR@polyphor.com 

About Polyphor

Polyphor is a research-oriented Swiss biopharmaceutical company with a leading macrocyclic peptide technology platform. Polyphor is headquartered in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). www.polyphor.com.

About EnBiotix

Enbiotix is a privately-held, rare disease company with an initial focus on chronic respiratory diseases. EnBiotix is headquartered in Boston, Massachussets, USA with its affiliate, EnBiotix, GmbH based in Leipzig, Germany. www.enbiotix.com

Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

-----------------------------------------------------------------------------------------------------------------------

End of ad hoc announcement

-----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      Polyphor AG 
              Hegenheimermattweg 125 
              4123 Allschwil 
              Switzerland 
Phone:        +41 61 567 1600 
Fax:          +41 61 567 1601 
E-mail:       info@polyphor.com 
Internet:     www.polyphor.com 
ISIN:         CH0106213793 
Valor:        POLN 
Listed:       SIX Swiss Exchange 
EQS News ID:  1232536 
 
End of Announcement EQS Group News Service 
=------------ 

1232536 10-Sep-2021 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1232536&application_name=news

(END) Dow Jones Newswires

September 10, 2021 01:30 ET (05:30 GMT)

All news about POLYPHOR AG
10/15POLYPHOR : Exempted From Public Tender Offer Obligation In Merger With EnBiotix
MT
10/15La Commission des OPA constate l'absence d'obligation de présenter une offre publique d..
DJ
10/15Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeover Offer ..
DJ
10/14Polyphor to Seek Acquisitions
CI
09/27Polyphor publishes invitation to Extraordinary General Meeting and announces financial ..
DJ
09/27Polyphor AG Announces Executive Changes
CI
09/10POLYPHOR : Wraps Up Sale Of Inhaled Murepavadin To EnBiotix
MT
09/10Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by ..
DJ
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01POLYPHOR : Signs All-Stock Merger Deal With Rare Disease Company EnBiotix
MT
More news
Financials
Sales 2021 1,00 M 1,08 M 1,08 M
Net income 2021 -41,4 M -44,8 M -44,8 M
Net Debt 2021 76,8 M 83,2 M 83,2 M
P/E ratio 2021 -0,48x
Yield 2021 -
Capitalization 22,3 M 24,1 M 24,1 M
EV / Sales 2021 99,1x
EV / Sales 2022 5,68x
Nbr of Employees 52
Free-Float 82,3%
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | POLN | CH0106213793 | MarketScreener
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Last Close Price 1,81 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
G÷khan Batur Chief Executive Officer
Hernan Levett Chief Financial Officer
Kuno Sommer Chairman
Daniel Obrecht Chief Scientific Officer
Frank T. Weber Chief Medical & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
POLYPHOR AG-78.23%24
CSL LIMITED5.08%100 326
WUXI BIOLOGICS (CAYMAN) INC.6.42%59 129
SAMSUNG BIOLOGICS CO.,LTD.5.21%47 927
BIOGEN INC.16.50%42 513
ALEXION PHARMACEUTICALS, INC.0.00%40 336